The European stock market has recently seen a positive shift, with the pan-European STOXX Europe 600 Index rising by 1.40%, driven by optimism surrounding potential lower U.S. borrowing costs. Amidst this backdrop, penny stocks—often smaller or newer companies—present intriguing growth opportunities due to their typically lower price points and potential for significant upside when backed by strong financials. While the term "penny stocks" might seem outdated, these investments remain relevant for those seeking under-the-radar opportunities that combine value and growth potential in today's market landscape.
Top 10 Penny Stocks In Europe
| Name | Share Price | Market Cap | Rewards & Risks |
| Ariston Holding (BIT:ARIS) | €4.56 | €1.58B | ✅ 4 ⚠️ 2 View Analysis > |
| Maps (BIT:MAPS) | €3.36 | €44.63M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (DB:0QM) | €0.37 | €246.7M | ✅ 2 ⚠️ 2 View Analysis > |
| IAMBA Arad (BVB:FERO) | RON0.498 | RON16.84M | ✅ 2 ⚠️ 4 View Analysis > |
| Cellularline (BIT:CELL) | €3.15 | €66.44M | ✅ 4 ⚠️ 2 View Analysis > |
| Euroland Société anonyme (ENXTPA:ALERO) | €3.00 | €9.52M | ✅ 2 ⚠️ 5 View Analysis > |
| ForFarmers (ENXTAM:FFARM) | €4.645 | €410.55M | ✅ 4 ⚠️ 1 View Analysis > |
| Deceuninck (ENXTBR:DECB) | €2.12 | €293.03M | ✅ 4 ⚠️ 1 View Analysis > |
| Netgem (ENXTPA:ALNTG) | €0.942 | €31.77M | ✅ 4 ⚠️ 2 View Analysis > |
Click here to see the full list of 343 stocks from our European Penny Stocks screener.
Here's a peek at a few of the choices from the screener.
Tractial (ENXTPA:ALTRA)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Tractial S.A. offers payment solution services in France and has a market cap of €12.97 million.
Operations: The company generates revenue from two main segments: Production Sold (€0.90 million) and Provision of Services (€1.46 million).
Market Cap: €12.97M
Tractial S.A., with a market cap of €12.97 million, offers payment solutions in France and generates revenue from Production Sold (€0.90 million) and Provision of Services (€1.46 million). The company's share price has been highly volatile over the past three months, reflecting typical penny stock characteristics. Tractial is currently unprofitable, with increasing losses over the past five years at a rate of 32.3% annually. Despite this, its short-term assets exceed both short- and long-term liabilities, indicating some financial stability. Recent private placements have bolstered its cash runway to approximately seven months, though further capital may be needed soon.
- Navigate through the intricacies of Tractial with our comprehensive balance sheet health report here.
- Assess Tractial's previous results with our detailed historical performance reports.
Uniphar (ISE:UPR)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Uniphar plc is a diversified healthcare services company operating in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally with a market cap of €1.06 billion.
Operations: The company's revenue is derived from three main segments: Pharma (€658.81 million), Medtech (€267.97 million), and Supply Chain & Retail (€1.84 billion).
Market Cap: €1.06B
Uniphar, with a market cap of €1.06 billion, operates across Pharma, Medtech, and Supply Chain & Retail segments. The company recently secured an exclusive distribution agreement for AGAMREE in the Middle East, potentially enhancing its revenue streams in 2026. Its earnings have grown significantly over the past year by 43.3%, outpacing industry averages and showing accelerated profit growth compared to its five-year trend. Despite some volatility and a low return on equity at 16%, Uniphar's debt is well-managed with satisfactory net debt levels and strong operating cash flow coverage of debt obligations.
- Dive into the specifics of Uniphar here with our thorough balance sheet health report.
- Review our growth performance report to gain insights into Uniphar's future.
Exasol (XTRA:EXL)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Exasol AG develops databases for analytics and data warehousing across Germany, Austria, Switzerland, Great Britain, North America, and internationally with a market cap of €90.39 million.
Operations: The company's revenue is primarily generated from the DACH region with €28.07 million, followed by North America at €7.72 million, Great Britain contributing €2.01 million, and the Rest of Europe and Rest of World accounting for €3.83 million.
Market Cap: €90.39M
Exasol has transitioned to profitability, with earnings growth making comparisons to past averages challenging. The company is debt-free, which eliminates concerns about interest coverage and highlights its financial stability. Exasol's short-term assets of €23.3 million comfortably cover both short-term (€1.3 million) and long-term liabilities (€18.7 million). Recent earnings reports show sales of €21.47 million for the half-year ending June 2025, up from €19.44 million a year prior, with net income reaching €1.37 million compared to a previous net loss. The management anticipates mid-single-digit revenue growth for the full fiscal year 2025.
- Take a closer look at Exasol's potential here in our financial health report.
- Evaluate Exasol's prospects by accessing our earnings growth report.
Summing It All Up
- Unlock our comprehensive list of 343 European Penny Stocks by clicking here.
- Want To Explore Some Alternatives? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Exasol might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com